相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
Kensei Tobinai et al.
ADVANCES IN THERAPY (2017)
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
Jun Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
Bo Cai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Yongxian Hu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Hanren Dai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Sebastien Maury et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Hanren Dai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor
Simon Lumb et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2016)
Monoclonal antibodies in acute lymphoblastic leukemia
Elias Jabbour et al.
BLOOD (2015)
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2015)
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre-B-ALL
Aradhana Awasthi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Redirection of CD4+and CD8+T lymphocytes via an anti-CD3 x anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells
Dongmei Fan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia
Kanti R. Rai
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Bispecific antibodies and their applications
Gaowei Fan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
Thomas Koehnke et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Chimeric Antigen Receptor Therapy for Cancer
David M. Barrett et al.
ANNUAL REVIEW OF MEDICINE, VOL 65 (2014)
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Marcela V. Maus et al.
BLOOD (2014)
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Dieter Hoelzer et al.
BLOOD (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia
Anjali S. Advani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Toxicity management for patients receiving novel T-cell engaging therapies
David M. Barrett et al.
CURRENT OPINION IN PEDIATRICS (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
T-Cell Immunotherapy: Looking Forward
Jacqueline Corrigan-Curay et al.
MOLECULAR THERAPY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso et al.
BLOOD (2013)
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Conrad Russell Y. Cruz et al.
BLOOD (2013)
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
James N. Kochenderfer et al.
BLOOD (2013)
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia Results of cancer and leukemia group B study 19802
Wendy Stock et al.
CANCER (2013)
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
Hagop Kantarjian et al.
CANCER (2013)
The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
Hernan Carol et al.
CLINICAL CANCER RESEARCH (2013)
High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations
Jawad Francis et al.
LEUKEMIA & LYMPHOMA (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
PLOS ONE (2013)
Lessons learned from a highly-active CD22-specific chimeric antigen receptor
Adrienne H. Long et al.
ONCOIMMUNOLOGY (2013)
Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia
Elias J. Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Veronique Blanc et al.
CLINICAL CANCER RESEARCH (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
Sebastien Maury et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
Deborah A. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts
Renier J. Brentjens et al.
CLINICAL CANCER RESEARCH (2007)
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
H Kantarjian et al.
BLOOD (2003)
分享论文
